Viridian Therapeutics/$VRDN
1D1W1MYTD1Y5YMAX
Capital at risk
About Viridian Therapeutics
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
- Ticker
- $VRDN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 252
- Headquarters
- Waltham, United States
- Website
- www.viridiantherapeutics.com
VRDN Metrics
BasicAdvanced
$2.4B
-
-$3.46
0.96
-
Price and volume
Market cap
$2.4B
Beta
0.96
52-week high
$34.29
52-week low
$13.18
Average daily volume
1.5M
Financial strength
Current ratio
16.949
Quick ratio
16.562
Long term debt to equity
0.369
Total debt to equity
0.37
Interest coverage (TTM)
-25.95%
Profitability
EBITDA (TTM)
-404.731
Gross margin (TTM)
-356.47%
Net profit margin (TTM)
-544.06%
Operating margin (TTM)
-569.68%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-30.16%
Return on equity (TTM)
-65.74%
Valuation
Price to revenue (TTM)
29.105
Price to book
4.3
Price to tangible book (TTM)
4.38
Price to free cash flow (TTM)
-6.179
Free cash flow yield (TTM)
-16.18%
Free cash flow per share (TTM)
-3.468
Growth
Revenue change (TTM)
23,220.33%
Earnings per share change (TTM)
-2.96%
3-year revenue growth (CAGR)
264.40%
3-year earnings per share growth (CAGR)
-11.26%
What the Analysts think about VRDN
Analyst ratings (Buy, Hold, Sell) for Viridian Therapeutics stock.
Analyst projections of the future price of Viridian Therapeutics stock.
Bulls say / Bears say
FDA approval of Lumvoa on June 26, 2026 gives Viridian its first commercial product and a differentiated label covering thyroid eye disease regardless of disease activity or duration, including both active and chronic TED. (Viridian Therapeutics)
Elegrobart produced positive Phase 3 results in both active and chronic TED, with statistically significant proptosis responses and generally favorable tolerability; if approved, its low-volume subcutaneous autoinjector could offer a more convenient at-home alternative and expand Viridian’s TED franchise. (Viridian Therapeutics)
Viridian had $981.5 million in cash, cash equivalents and marketable securities at June 30, 2026, supplemented by approximately $334.7 million of net proceeds from its May financing, providing substantial resources for Lumvoa commercialization, elegrobart development and earlier pipeline programs. (Viridian Therapeutics)
Lumvoa’s commercial execution remains unproven: first doses were administered only in July 2026, while payer-coverage work was still ongoing as of July 31; meanwhile, Q2 selling, general and administrative expense rose to $55.0 million and net loss reached $127.1 million. (Viridian Therapeutics)
Lumvoa carries meaningful treatment-burden and safety considerations: it requires five intravenous infusions over 12 weeks, with reported risks including infusion reactions in approximately 9% of patients, hyperglycemia in 12%, and potentially permanent hearing impairment. (Viridian Therapeutics)
Viridian increased financing risk in May 2026 by issuing $225.0 million of convertible notes and 7.35 million common shares; future conversion or further capital needs could dilute shareholders, particularly while the company remains loss-making. (Viridian Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
VRDN Financial Performance
Revenues and expenses
VRDN Earnings Performance
Company profitability
Upcoming events
No upcoming events
VRDN News
AllArticlesVideos
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
Business Wire2 months ago
Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease
Benzinga3 months ago
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
Business Wire3 months ago
Funds containing VRDN
AllUSDEURGBP
Fund name | Fund size | $VRDN weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.24% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.24% |
iShares Healthcare Innovation£DRDR | £1B | 0.24% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.08% |
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.